11174 related articles for article (PubMed ID: 10606355)
1. Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases.
Robins HI; Grosen E; Katschinski DM; Longo W; Tiggelaar CL; Kutz M; Winawer J; Graziano F
J Rheumatol; 1999 Dec; 26(12):2513-6. PubMed ID: 10606355
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.
Robins HI; Rushing D; Kutz M; Tutsch KD; Tiggelaar CL; Paul D; Spriggs D; Kraemer C; Gillis W; Feierabend C; Arzoomanian RZ; Longo W; Alberti D; d'Oleire F; Qu RP; Wilding G; Stewart JA
J Clin Oncol; 1997 Jan; 15(1):158-64. PubMed ID: 8996137
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.
Robins HI; Katschinski DM; Longo W; Grosen E; Wilding G; Gillis W; Kraemer C; Tiggelaar CL; Rushing D; Stewart JA; Spriggs D; Love R; Arzoomanian RZ; Feierabend C; Alberti D; Morgan K; Simon K; d'Oleire F
Cancer Chemother Pharmacol; 1999; 43(5):409-14. PubMed ID: 10100597
[TBL] [Abstract][Full Text] [Related]
4. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.
Atanackovic D; Nierhaus A; Neumeier M; Hossfeld DK; Hegewisch-Becker S
Cancer Immunol Immunother; 2002 Dec; 51(11-12):603-13. PubMed ID: 12439605
[TBL] [Abstract][Full Text] [Related]
5. [Serum levels and urinary excretion of soluble receptors for tumor necrosis factor (sTNF R) in patients with primary glomerulonephritis].
Kacprzyk F
Pol Arch Med Wewn; 2002 Mar; 107(3):215-21. PubMed ID: 12107979
[TBL] [Abstract][Full Text] [Related]
6. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease.
Robins HI; D'Oleire F; Grosen E; Spriggs D
Anticancer Res; 1997; 17(4B):2891-4. PubMed ID: 9329556
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.
Robins HI; d'Oleire F; Kutz M; Bird A; Schmitt-Tiggelaar CL; Cohen JD; Spriggs DR
Cancer Lett; 1995 Feb; 89(1):55-62. PubMed ID: 7882302
[TBL] [Abstract][Full Text] [Related]
8. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in patients with bulimia nervosa.
Nakai Y; Hamagaki S; Takagi R; Taniguchi A; Kurimoto F
Clin Endocrinol (Oxf); 2000 Sep; 53(3):383-8. PubMed ID: 10971457
[TBL] [Abstract][Full Text] [Related]
10. Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2002 Dec; 57(6):805-11. PubMed ID: 12460331
[TBL] [Abstract][Full Text] [Related]
11. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients.
Jabłońska E; Pietruska Z
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):449-53. PubMed ID: 9437501
[TBL] [Abstract][Full Text] [Related]
12. [Tumor necrosis factor receptors sTNF-RI and sTNF-RII in advanced chronic heart failure].
Nowak J; Rozentryt P; Szewczyk M; Gierlotka M; Duszańska A; Szyguła B; Wojnicz R; Hawranek M; Poloński L; Zembala M
Pol Arch Med Wewn; 2002 Mar; 107(3):223-9. PubMed ID: 12107980
[TBL] [Abstract][Full Text] [Related]
13. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.
Ribbens C; André B; Kaye O; Kaiser MJ; Bonnet V; de Groote D; Franchimont N; Malaise MG
Eur Cytokine Netw; 2000 Dec; 11(4):669-76. PubMed ID: 11125312
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C.
Fabris C; Del Forno M; Falleti E; Toniutto P; Pirisi M
Clin Exp Immunol; 1999 Sep; 117(3):556-60. PubMed ID: 10469062
[TBL] [Abstract][Full Text] [Related]
15. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis.
Nakayama T; Hashimoto S; Amemiya E; Horie T
Clin Exp Immunol; 1996 May; 104(2):318-24. PubMed ID: 8625527
[TBL] [Abstract][Full Text] [Related]
16. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
[TBL] [Abstract][Full Text] [Related]
17. Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery.
Sulyok I; Fleischmann E; Stift A; Roth G; Lebherz-Eichinger D; Kasper D; Spittler A; Kimberger O
Br J Anaesth; 2012 Nov; 109(5):754-61. PubMed ID: 22855633
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure.
Nozaki N; Yamaguchi S; Yamaoka M; Okuyama M; Nakamura H; Tomoike H
J Mol Cell Cardiol; 1998 Oct; 30(10):2003-12. PubMed ID: 9799654
[TBL] [Abstract][Full Text] [Related]
19. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group.
Girardin E; Roux-Lombard P; Grau GE; Suter P; Gallati H; Dayer JM
Immunology; 1992 May; 76(1):20-3. PubMed ID: 1321092
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of TNF-alpha, sTNF-RI and sTNF-RII in murine schistosomiasis correlate with schistosome oviposition and circumoval granuloma formation.
Haseeb MA; Shirazian DJ; Preis J
Cytokine; 2001 Sep; 15(5):266-9. PubMed ID: 11594791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
